Biotechnology Innovation Organization· @IAmBiotech · X·· 22 天前精选AI 评分62
AI 导读
Teva宣布FDA已批准其用于精神分裂症的新型长效治疗药物Weltruza。BIO称这是首个每月一次皮下注射的奥氮平制剂,且给药后无需监测,美国约210万精神分裂症患者可能因此受益。
推荐理由
该药为FDA批准的首个每月一次皮下注射奥氮平,且无需给药后监测,读者可据此了解精神分裂症长效治疗的新选项。
正文
A meaningful step forward for the 2.1 million Americans living with schizophrenia -> Congratulations to @TevaUSA on FDA approval of Weltruza - the first once-monthly olanzapine injection given under the skin, with no post-dose monitoring required.
BREAKING: The FDA has granted approval of our new schizophrenia long-acting treatment option. Read more from today’s announcement here: https://ow.ly/9sjW50ZWenA $TEVA在 X 查看被引用的帖子
来源:Biotechnology Innovation Organization · x.com